Complement Mediators in Development to Treat Age-Related Macular Degeneration

Drugs Aging. 2022 Feb;39(2):107-118. doi: 10.1007/s40266-021-00914-x. Epub 2022 Jan 20.

Abstract

Over recent years, great attention has been paid to the role of the complement system in the pathogenesis of age-related macular degeneration (AMD). In particular, several studies have highlighted a link between AMD development and complement dysregulation, which can probably be explained as a complement cascade hyperactivation resulting from the presence of a series of risk factors such as aging; smoking; obesity; alcohol consumption; exposure to pesticides, industrial chemicals, or pollution; and other causes of oxidative stress. This hypothesis has been mainly supported by the presence of complement mediators as constituents of drusen, representing one of the earliest and most characteristic signs of retinal damage in AMD. Additionally, activated complement mediators and some complement regulators, such as vitronectin, have been found not only in the drusen and adjacent retinal areas but also in the peripheral blood of patients with AMD. Therefore, we aim to provide a review of recently studied complement factors to highlight their role in the pathogenesis of AMD and to evaluate new potential therapeutic strategies.

Publication types

  • Review

MeSH terms

  • Aging / physiology
  • Complement Activation
  • Complement System Proteins / metabolism
  • Humans
  • Macular Degeneration*
  • Oxidative Stress

Substances

  • Complement System Proteins